SG11201401895WA - Administration of nedd8-activating enzyme inhibitor and hypomethylating agent - Google Patents

Administration of nedd8-activating enzyme inhibitor and hypomethylating agent

Info

Publication number
SG11201401895WA
SG11201401895WA SG11201401895WA SG11201401895WA SG11201401895WA SG 11201401895W A SG11201401895W A SG 11201401895WA SG 11201401895W A SG11201401895W A SG 11201401895WA SG 11201401895W A SG11201401895W A SG 11201401895WA SG 11201401895W A SG11201401895W A SG 11201401895WA
Authority
SG
Singapore
Prior art keywords
nedd8
administration
enzyme inhibitor
activating enzyme
hypomethylating agent
Prior art date
Application number
SG11201401895WA
Inventor
Peter G Smith
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of SG11201401895WA publication Critical patent/SG11201401895WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201401895WA 2011-11-03 2012-11-02 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent SG11201401895WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555049P 2011-11-03 2011-11-03
PCT/US2012/063382 WO2013067396A2 (en) 2011-11-03 2012-11-02 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent

Publications (1)

Publication Number Publication Date
SG11201401895WA true SG11201401895WA (en) 2014-05-29

Family

ID=48193039

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201401895WA SG11201401895WA (en) 2011-11-03 2012-11-02 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent

Country Status (22)

Country Link
US (2) US8980850B2 (en)
EP (1) EP2773360B1 (en)
JP (2) JP6231988B2 (en)
KR (1) KR101987861B1 (en)
CN (1) CN104245699B (en)
AU (1) AU2012321106C1 (en)
BR (1) BR112014010699B1 (en)
CA (1) CA2854461C (en)
EA (1) EA028380B1 (en)
ES (1) ES2668272T3 (en)
GE (1) GEP20196940B (en)
HK (1) HK1201733A1 (en)
IL (1) IL232353B (en)
MA (1) MA35662B1 (en)
MX (1) MX357835B (en)
MY (1) MY176125A (en)
PL (1) PL2773360T3 (en)
SG (1) SG11201401895WA (en)
TN (1) TN2014000194A1 (en)
TR (1) TR201807342T4 (en)
UA (1) UA114414C2 (en)
WO (1) WO2013067396A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104016987A (en) 2009-05-14 2014-09-03 米伦纽姆医药公司 Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
JP6038150B2 (en) * 2011-08-24 2016-12-07 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． NEDD8 activating enzyme inhibitor
EP2764866A1 (en) * 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
JP6556701B2 (en) 2013-05-14 2019-08-07 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Administration of NEDD8 activating enzyme inhibitor and chemotherapeutic agent
US20150031643A1 (en) * 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome ii
KR102359214B1 (en) 2014-04-04 2022-02-07 델 마 파마슈티컬스 Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CN103948590A (en) * 2014-05-22 2014-07-30 中国药科大学 NEDD8 (neural precursor cell-expressed developmentally downregulated 8)activating enzyme inhibitor and medical application thereof
SG10201912869WA (en) * 2015-10-15 2020-02-27 Celgene Corp Combination therapy for treating malignancies
US11701406B2 (en) 2017-05-25 2023-07-18 The Board Of Trustees Of The Leland Stanford Junior University Combination of low dose IL-2 and an inhibitor of Treg IL-2R desensitization to treat autoimmune and allergic inflammatory diseases
WO2019060536A1 (en) * 2017-09-21 2019-03-28 Millennium Pharmaceuticals, Inc. Cocrystal forms of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof
EP3883597A2 (en) * 2018-11-20 2021-09-29 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease
SG11202110092PA (en) 2019-03-15 2021-10-28 Fulcrum Therapeutics Inc Macrocyclic azolopyridine derivatives as eed and prc2 modulators
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy
WO2023242235A1 (en) * 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
CN115007323B (en) * 2022-06-17 2024-01-23 中南大学 Method for inhibiting pyrite floatation in minerals
WO2024012414A1 (en) * 2022-07-11 2024-01-18 Westlake University Use of a fbxo42 specific inhibitor in treating notch signaling-dependent disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
CA2596424C (en) 2005-02-04 2016-03-29 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
KR101450535B1 (en) 2006-02-02 2014-10-14 밀레니엄 파머슈티컬스 인코퍼레이티드 Inhibitors of e1 activating enzyme
EA201501088A1 (en) * 2006-08-08 2017-01-30 Миллениум Фармасьютикалз, Инк. Heteroaryl Compounds Used as E1 Inhibitors Activating Enzymes
WO2008028193A2 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
JP2011505336A (en) 2007-11-01 2011-02-24 セルジーン コーポレイション Cytidine analogs for the treatment of myelodysplastic syndrome
WO2009106549A2 (en) * 2008-02-26 2009-09-03 Nerviano Medical Sciences S.R.L. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
LT3782612T (en) 2008-05-15 2023-12-27 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
NZ589719A (en) * 2008-06-09 2012-08-31 Cyclacel Ltd Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
CN102438588B (en) * 2009-03-23 2015-04-01 埃姆比特生物科学公司 Methods of treatment using combination therapy
CN104016987A (en) 2009-05-14 2014-09-03 米伦纽姆医药公司 Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
MX2013006020A (en) 2011-01-31 2013-10-01 Celgene Corp Pharmaceutical compositions of cytidine analogs and methods of use thereof.
JP6162709B2 (en) 2011-11-01 2017-07-12 セルジーン コーポレイション Methods of treating cancer using oral preparations of cytidine analogs

Also Published As

Publication number Publication date
WO2013067396A2 (en) 2013-05-10
MY176125A (en) 2020-07-24
MX2014005323A (en) 2014-06-05
AU2012321106B2 (en) 2016-08-04
NZ624881A (en) 2016-10-28
EP2773360A2 (en) 2014-09-10
UA114414C2 (en) 2017-06-12
US20150366886A1 (en) 2015-12-24
AU2012321106C1 (en) 2016-11-24
KR20140097229A (en) 2014-08-06
US8980850B2 (en) 2015-03-17
JP6231988B2 (en) 2017-11-15
EA201400539A1 (en) 2014-12-30
JP2015505816A (en) 2015-02-26
HK1201733A1 (en) 2015-09-11
EP2773360B1 (en) 2018-02-28
KR101987861B1 (en) 2019-06-11
US20130116208A1 (en) 2013-05-09
JP2018009035A (en) 2018-01-18
TN2014000194A1 (en) 2015-09-30
PL2773360T3 (en) 2018-09-28
CA2854461C (en) 2021-01-19
MX357835B (en) 2018-07-26
CN104245699A (en) 2014-12-24
CN104245699B (en) 2017-06-27
IL232353A0 (en) 2014-06-30
ES2668272T3 (en) 2018-05-17
EP2773360A4 (en) 2015-09-23
GEP20196940B (en) 2019-01-10
IL232353B (en) 2018-11-29
AU2012321106A1 (en) 2013-05-23
MA35662B1 (en) 2014-11-01
BR112014010699A2 (en) 2017-04-25
BR112014010699B1 (en) 2020-12-15
CA2854461A1 (en) 2013-05-10
TR201807342T4 (en) 2018-06-21
EA028380B1 (en) 2017-11-30
WO2013067396A3 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
HK1201733A1 (en) Administration of nedd8-activating enzyme inhibitor and hypomethylating agent nedd8-
HRP20180953T1 (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
HK1246674A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
HK1203853A1 (en) Inhibitors of arginase and their therapeutic applications
EP2678018A4 (en) Combination of kanase inhibitors and uses thereof
HK1202112A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
HK1202244A1 (en) Prebiotic formulations and methods of use
EP2721019A4 (en) Therapeutically active compositions and their methods of use
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
EP2790709A4 (en) Hemostatic agents and methods of use
IL232115A0 (en) Pharmaceutical compositions comprising dgla and /or 15-hetre and methods of use thereof
EP2635287A4 (en) Administration of nedd8-activating enzyme inhibitor
HK1201066A1 (en) Pyranopyridone inhibitors of tankyrase
EP2688901A4 (en) INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10